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Abstract: Binge-eating behavior involves rapid consumption of highly 
palatable foods leading to increased weight gain. Feeding in binge disorders 
resembles other compulsive behaviors, many of which are responsive to N-
acetylcysteine (NAC), which is a cysteine prodrug often used to promote non-
vesicular glutamate release by a cystine–glutamate antiporter. To examine 
the potential for NAC to alter a form of compulsive eating, we examined the 
impact of NAC on binge eating in a rodent model. Specifically, we monitored 
consumption of standard chow and a high-fat, high carbohydrate western diet 
(WD) in a rodent limited-access binge paradigm. Before each session, rats 
received either a systemic or intraventricular injection of NAC. Both systemic 
and central administration of NAC resulted in significant reductions of binge 
eating the WD without decreasing standard chow consumption. The reduction 
in WD was not attributable to general malaise as NAC did not produce 
condition taste aversion. These results are consistent with the clinical 
evidence of NAC to reduce or reverse compulsive behaviors, such as, drug 
addiction, skin picking and hair pulling. 
Introduction 
Binge eating is one of the most prevalent eating disorders in the 
United States, and contributes to the obesity epidemic that is currently 
endangering the health of ~30% of all Americans.1, 2 Feeding in binge 
disorders is characterized by rapid consumption of large amounts of 
highly palatable food that occur in very short periods of time.3 These 
maladaptive alterations in feeding behavior culminate in a destructive 
state that often parallels other compulsive disorders, such as drug 
addiction.4, 5 In many instances, binge eating is reported to occur in 
the absence of hunger, suggesting that this compulsive feeding state 
could arise from excessive hedonic drive rather than unmet 
homeostatic needs.6, 7 
Many compulsive disorders involve abnormal glutamatergic 
signaling.8 Likely because of this, the cysteine prodrug N-
acetylcysteine (NAC) has been shown to reduce many forms of 
compulsive behaviors ranging from addiction to trichotillomania.9, 10 
The mechanism of action of NAC typically involves increasing the 
activity of the cystine–glutamate antiporter system xc−,11 which has 
been shown to be a key component of glutamate homeostasis by 
maintaining extrasynaptic glutamate tone via non-vesicular release 
and, in turn, affecting receptor function (i.e., synaptic signaling) in 
regions implicated in hedonic motivated eating.12, 13 System xc− has 
been shown to be an effective target to inhibit cocaine-induced 
behaviors and reinstatement in preclinical studies.14 Because of the 
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compulsive aspect of binge eating, an overeating behavior analogous 
to drug abuse, we examine the potential for systemic or 
intraventricular (ICV) administration of NAC to alter binge eating. In 
the current study, we utilized a frequently employed preclinical model 
of binge eating in which rodents are permitted daily limited access to a 
highly palatable food as an adjunct to their ad libitum standard chow 
(SC) and recapitulates several characteristics of human binge-eating 
disorder.15 
Methods 
Animals 
Male Sprague–Dawley rats (225–250 g; 53–58-days-old; 
Harlan; Indianapolis, IN, USA) were housed individually under a 12 h 
light/dark cycle (2PM: Lights OFF; 2AM: Lights ON) with ad libitum 
access to a Harlan standard diet (8604 formula) for the duration of all 
experiments. Intake was monitored daily via a BioDAQ Food Intake 
Monitor (Research Diets, New Brunswick, NJ, USA) or by pre-weighing 
food bins before and after experimental sessions. Body weights were 
also recorded daily. All procedures using animals were approved by the 
Marquette University Institutional Animal Care and Use Committee. 
Cannulation surgery and microinjections 
Animals were anesthetized with a 
ketamine/xylazine/acepromazine (77:1.5:1.5 mg−1 ml−1 kg−1; 
intraperitoneal (i.p.)) cocktail and placed in a stereotaxic apparatus. A 
26 gauge unilateral guide cannula (Plastics One; Roanoke, VA, USA) 
was placed into a lateral ventricle and secured to the skull via an 
acrylic resin. The stereotaxic coordinates were anterior/posterior, 
−0.8 mm from bregma; medial/lateral, ±1.5 mm from midline; 
dorsal/ventral, −3.0 mm from the surface of the skull, whereas the 
injector extended 0.5 mm further beyond the tip of the guide cannula. 
Stereotaxic coordinates were based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition.16 
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Limited access binge-eating model 
Animals with ad libitum access to SC (Harlan 8604 formula; SC; 
32% of total kilocalorie (kcal) protein, 54% of total kcal carbohydrate, 
14% of total kcal fat; 3.0 kcal g−1) were additionally allowed daily 
limited access (30 min day−1) to a highly palatable western diet (WD; 
Research Diets; New Brunswick, NJ, USA; 17% of total kcal protein, 
43% of total kcal carbohydrate, 41% of total kcal fat; 4.7 kcal g−1) 
shortly after lights out (45 min). Chronic systemic (i.p.; 90 mg kg−1) 
and intermittent central (ICV; 10 μg/ 5μl) NAC was administered 45–
60 min before gaining limited access to WD based on previous work 
examining the preclinical therapeutic potential of systemic and 
centrally administered NAC in attenuating cocaine-relapse behavior in 
rodents.17 
Chronic systemic NAC 
Animals (n=12–17/treatment) received chronic i.p. injections of 
either vehicle (saline) or NAC (90 mg kg−1) 45–60 min before gaining 
limited access (30 min day−1) to the pre-weighed bin of WD for 14 
days. 
Central NAC 
After a 1 week period of recovery from guide cannula surgery, 
animals (n=6–8/dose) were placed on the limited-access binge 
paradigm for 7 days during which NAC was injected into the cerebral 
ventricles on alternating days. On days 1, 3, 5 and 7 animals received 
central infusions of NAC (10 μg/5 μl) whereas control animals received 
an equal volume of vehicle (saline); microinjections were preformed 
1 h before WD access. Animals were given daily access (30 min day−1) 
to WD to avoid associating bin access with any protocol associated 
with microinjections. 
Conditioned taste aversion 
A separate group of animals were habituated to restricted water 
access (1 h day−1) and systemic injections (i.p.) of saline 45–60 min 
before water access for 1 week. Subsequently, animals were separated 
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into three treatment groups (n=5/group): saline, NAC (90 mg kg−1) or 
LiCl (2%; i.p.), and offered two bottles each containing a 0.15% 
saccharin solution for 24 h then returned to their previous restricted 
water conditions. Two days later, animals were provided a two-bottle 
choice test with one bottle containing 0.15% saccharin solution and 
the other containing water for 1 h. 
Statistics 
Data are presented as means±standard errors of the mean, and 
were analyzed statistically (Sigma Plot 11; Systat Software Inc.; San 
Jose, CA, USA) by analysis of variance (with repeated measures when 
appropriate) or student’s t-test. Fischer LSD analysis was used for all 
post-hoc group comparisons. P values <0.05 were considered 
statistically significant. 
Results 
Daily systemic injections of NAC (90 mg kg−1; i.p.) or vehicle 
(saline) injections were administered 45 min before limited access 
(30 min day−1) to a highly palatable WD as an adjunct to ad libitum SC 
for 14 days. Animals treated with NAC ate significantly less WD (Figure 
1a; treatment F(1,405)= 5.478; P<0.03), and significantly more SC 
(Figure 1b; treatment F(1,405)=4.893; P<0.04) over the 2 week 
study. As expected, NAC-treated animals displayed a significantly 
larger percentage of daily kcal ingested from SC and a concomitant 
reduction in WD intake than vehicle-treated rats by the 14th day of 
experimentation (Figure 1c; left; P<0.05). The compensatory increase 
in SC consumption paired with the attenuation in WD consumption 
resulted in no significant change in total calories consumed or body 
weight gain (Figures 1d and e). In a separate study, NAC administered 
centrally every 48 h (before WD access) at the onset of dark via ICV 
injections displayed a similar suppression in the escalation of WD 
consumption over a 7 day period (Figure 1f; treatment × time, F(6, 
97)= 2.281; P<0.05). 
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Figure 1. 
 
System (90 mg kg−1; i.p.) and central (10 μg/5μl) NAC alters binge behavior produced 
by daily limited access to a palatable food. (a) NAC-treated animals ate significantly 
less WD (30 min day−1) compared to saline-injected control animals. (b) Subsequently, 
NAC-treated animals ate significantly more SC over the duration of the study. (c) 
Percent kcal intake of SC on the 14th day is significantly higher for the NAC-treated 
group, whereas WD consumption was significantly decreased compared to the control 
group. (d, e) There is no significant difference in cumulative food intake or body 
weight gained between the two experimental groups. (f) In a separate study, animals 
received infusions (NAC or saline; ICV) 30 min before accessing WD, central 
administration of NAC significantly suppressed WD consumption over the 7 day study. 
Data expressed as mean±s.e.m. *P<0.05 compared to control group. 
The hypophagic effects of NAC appear to be specific to palatable 
WD consumption as it does not significantly alter the feeding behavior 
of animals maintained on ad ibitum SC only (Figure 2a). Moreover, 
there were no effects on SC consumption over the first 6 or 24 h after 
administration of NAC (data not shown). In addition, a conditioned-
taste aversion revealed that suppression of WD by NAC was not due to 
malaise (Figure 2b). 
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Figure 2. 
 
Systemic administration of NAC (90 mg kg−1; i.p.) does not alter ad libitum SC 
consumption or produce any conditioned-taste aversion. (a) Animals maintained on ad 
libitum SC and not subjected to a limited-access binge paradigm show no changes in 
feeding behavior measured 1 and 3 h post i.p. injection. (b) Saccharin preference ratio 
(%) of control (saline), NAC and LiCl (2% body weight)-treated animals produced only 
a significant suppression of saccharin consumption in the LiCl-treated group. Data 
expressed as mean±s.e.m. *P<0.05 compared to controls. 
Discussion 
Chronic systemic NAC significantly attenuates binge eating of a 
WD over a 14 day study (Figure 1). Although chronic NAC 
administration did not alter total caloric intake or weight gain (Figures 
1d and e), systemic or central administration was sufficient to reduce 
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intake of highly caloric and palatable food without inducing malaise 
(Figures 2b and c). This selectivity of NAC to regulate only WD 
consumption is quite notable as it suggests that system xc− activation 
does not impact overall caloric homeostasis but may lessen the 
hedonic drive for food. Future studies extending chronic NAC 
administration beyond 2 weeks may be necessary to demonstrate 
effects on long-term calorie consumption and body weight. 
NAC, a cysteine prodrug, has been demonstrated to drive the 
activity of the cystine–glutamate antiporter system xc−, which 
promotes non-vesicular glutamate release and consequently impact 
synaptic glutamate signaling, which is critical to the development and 
maintenance of a wide variety of compulsive behaviors.18, 19 In the 
case of long-term use of drugs of abuse, there is a reduction in system 
xc− activity in the nucleus accumbens, which is thought to contribute 
to the pathological glutamate signaling that in turn contributes to the 
addiction.20 Subsequently, both preclinical and clinical studies of NAC 
treatment have shown inhibition of cocaine-induced behaviors in 
animals and reduction in craving and/or use of cocaine and tobacco in 
humans.9, 20, 21 The effectiveness of NAC to reduce binge eating of a 
highly caloric palatable food is consistent with other studies 
demonstrating the attenuation of compulsive behaviors, such as, drug 
taking, hair pulling and skin picking, and suggests that system xc− is a 
potential therapeutic target for the treatment of compulsive feeding 
disorders.9, 10, 22 Pursuing effective treatments for compulsive eating 
disorders will require further understanding of the neural mechanisms 
that underlie hedonic drive.7 
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